Managing ESG Risk in Healthcare

Managing ESG Risk in Healthcare

Rob Larson • October 12, 2023
Rob Larson • October 12, 2023

Share

In the healthcare sector, the industry’s core mission revolves around enhancing and preserving lives, which can lead organizations to encounter a multifaceted array of Environmental, Social, and Governance (ESG) challenges. While these challenges are diverse and extend beyond the scope of this introduction, it's essential to identify, comprehend, and effectively manage them within a strategic ESG due diligence framework.

 

By taking a proactive approach to addressing ESG risks, organizations can ensure the delivery of equitable care, safeguarding of patient data, adherence to ethical business practices, and promotion of inclusivity in clinical trials. This comprehensive strategy not only ensures compliance but may also generate substantial value in a critical sector.

Identifying ESG Risks 

Within the healthcare industry, numerous pivotal ESG risks have been discerned; each serving as a fundamental catalyst in molding the future industry landscape. These risks form the core of our ESG due diligence framework and facilitate a comprehensive evaluation specific to an individual asset. Below, we delve into a select few key ESG risks within the domain:

Access to Care

Organizations delivering care or manufacturing medicines are under pressure to offer equitable access to care. They face reputational risks if they ignore the impact on groups of patients who are unequally afforded access to care. Ensuring access to quality healthcare for all is not only an ethical imperative but also a strategic necessity.

Patient Data Security

Patient data security is a direct risk for organizations that handle or protect patient data, including those involved in developing precision medicine. Safeguarding patient information is paramount not only to comply with regulations but also to maintain trust and confidence in healthcare services.

Business Ethics

Fee-for-service reimbursement models may incentivize health organizations to deliver more care than is medically necessary. This exposes them to regulatory and public scrutiny if ethical business practices are abused. Upholding the highest ethical standards in healthcare delivery is vital for maintaining public trust. 

Diversity & Inclusion in Clinical Trials

Companies developing medicines face growing public pressure to include a diverse and representative patient mix in clinical research trials. Ensuring diversity in clinical trials not only enhances the validity of research but also contributes to addressing healthcare disparities among different demographic groups.

ESG Due Diligence Process 

Stax’s ESG due diligence process involves a thorough assessment of material ESG risks across industries. We go beyond identification and provide strategic recommendations on how to track, monitor, and minimize risks during the ownership period. By implementing recommendations, organizations can ensure they are on the right path to meeting asset-specific ESG goals and responsibilities.


By proactively addressing ESG risks, organizations in the healthcare sector can enhance their reputations, strengthen patient trust, and contribute to the overall well-being of society. As the healthcare landscape evolves, it will become increasingly essential for organizations to embed ESG strategies into their operations, ensuring both patients and the healthcare ecosystem as a whole benefit. 

Image of Rob Larson

Managing Director | Healthcare

Read More

Grant Thornton Advisors Completes Acquisition of CBIZ
November 3, 2026
Grant Thornton Advisors LLC, New Mountain Capital, and CBIZ, Inc. today announced that Grant Thornton Advisors completed its acquisition of CBIZ. Read the full announcement here.
5 Key Takeaways from the Goodwin Pharma Services Symposium
By Jordan Abrams • October 30, 2026
Following the Goodwin Pharma Services Symposium, Jordan Abrams shares five key takeaways on the investment landscape for pharma services. Read his full list here.
Featured by ION Analytics: Private equity pays up for scale amid youth-enrichment platform scarcity
By Luke Scheibel • October 21, 2026
Luke Scheibel was interviewed by ION Analytics, where he shared his perspective on PE's rising interest in youth sports and the evolving investment considerations around them. Read more.
Paul Edwards & Robert Lytle Named Top PE Consultants & Leaders 2026
By Paul Edwards & Robert Lytle • October 21, 2026
Grant Thornton Stax is pleased to announce the naming of both Paul Edwards and Robert Lytle to The Consulting Report's Top Private Equity Consultants and Leaders of 2026. Read more here.
Feat. by Reuters: Chinese automakers make tech-led pitch for EU car market
By Brad Kuntz • October 16, 2026
Brad Kuntz was interviewed by Reuters to discuss how Chinese automakers are reshaping traditional perceptions of luxury in the EU automotive industry. Read the full story here.
The Investment Case for Experiential Marketing Agencies: Growing Mission Criticality of Live Events
By David Lindsay • October 15, 2026
Experiential marketing agencies are transforming into strategic partners, and enterprise clients are valuing agencies that create relationships built on trust and operational excellence. Read more.
Show More